NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.402) was uploaded to the NHS England Website on Thursday 4, June 2026.
The following changes have been introduced:
Mirvetuximab soravtansine (MIR1)
For treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Durvalumab with gemcitabine and cisplatin (DUR8)
For neoadjuvant treatment then alone adjuvant treatment of muscle-invasive bladder cancer where the following criteria have been met
Moved into routine commissioning - section B of list
Durvalumab with chemotherapy (DUR9)
For neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma where the following criteria have been met
Date moving into routine commissioning updated
Lisocabtagene maraleucel (LIS02a)
For treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL) to DLBCL in patients previously treated with two or more lines of systemic therapy where the following criteria have been met This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (LIS02b) can only be completed as a continuation of this first part of the form (LIS02a) and must be completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of lisocabtagene maraleucel.
Date moving into routine commissioning updated